22,275 GSK PLC Sponsored ADR $GSK Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK – Free Report) by 2.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,060,376 shares of the pharmaceutical company’s stock after buying an additional 22,275 shares during the period. Russell Investments Group Ltd.’s holdings in GSK were worth $51,078,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Natural Investments LLC lifted its position in GSK by 2.8% during the 2nd quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company’s stock worth $405,000 after buying an additional 211 shares in the last quarter. Flagship Harbor Advisors LLC boosted its stake in shares of GSK by 2.1% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,089 shares of the pharmaceutical company’s stock worth $486,000 after buying an additional 211 shares during the last quarter. Founders Financial Securities LLC grew its holdings in shares of GSK by 1.0% in the 3rd quarter. Founders Financial Securities LLC now owns 21,884 shares of the pharmaceutical company’s stock valued at $1,054,000 after acquiring an additional 211 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of GSK by 3.8% in the 3rd quarter. Grove Bank & Trust now owns 5,859 shares of the pharmaceutical company’s stock valued at $282,000 after acquiring an additional 215 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co grew its holdings in shares of GSK by 1.0% in the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 23,083 shares of the pharmaceutical company’s stock valued at $1,112,000 after acquiring an additional 222 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Citigroup assumed coverage on GSK in a research report on Friday, July 24th. They issued a “neutral” rating on the stock. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a research report on Sunday, August 2nd. HSBC restated a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Finally, Royal Bank Of Canada initiated coverage on GSK in a research note on Tuesday, September 8th. They issued a “sector perform” rating for the company. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, GSK has an average rating of “Hold” and a consensus target price of $56.30.

View Our Latest Report on GSK

GSK Stock Up 0.1%

Shares of GSK stock opened at $50.49 on Monday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.56 and a current ratio of 0.86. The firm’s 50-day moving average is $49.30 and its 200-day moving average is $52.40. The stock has a market cap of $102.13 billion, a price-to-earnings ratio of 17.54, a PEG ratio of 2.27 and a beta of 0.28. GSK PLC Sponsored ADR has a 52-week low of $45.81 and a 52-week high of $61.69.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be issued a dividend of $0.4518 per share. The ex-dividend date is Friday, November 13th. This is an increase from GSK’s previous quarterly dividend of $0.4515. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. GSK’s dividend payout ratio is 61.81%.

GSK Profile

(Free Report)

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

Recommended Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK – Free Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.